|
What Does Science Say About Omega-3 Fatty Acids and
Specific conditions ?
Minami Nutrition is about proof NOT
promises. Our product range are produced as a result
of our committment to research that examines the effect
of Omega-3 fats on a variety of medical areas, including
Dyslexia, Dyspraxia, Attention Deficit Hyperactivity
Disorder (AD/HD) as well as Heart Disease and Wellness
issues.
Clinical studies show that Omega-3
fatty acids are well tolerated by children and adults.
The general consensus is that 1 g of EPA + DHA per day
is sufficient to maintain optimum performance of the
cardiovascular system in most people.*
Ongoing scientific research is revealing
more about the enormous potential for Omega-3 fatty
acids to positively impact on a range of health outcomes.*
Heart and Cardiovascular Disease*:
Prevention = 1 g EPA + DHA/day (1,2)
With high blood triglycerides = 2 to 4 g EPA + DHA/day
(1)
Attention Deficit Hyperactivity Disorder
(AD/HD), Dyslexia, Dyspraxia*:
0.5 to 1 g EPA/day (8)
Depression and Bipolar Disorder*:
1 to 2 g EPA/day as supplementary treatment with standard
therapy (3-5)
Schizophrenia*:
2 g EPA/day as supplementary treatment with standard
therapy (6)
Mood Disorder (aggression)*:
1 to 2 g EPA/day (7)
Pregnancy and Breast Feeding*:
220 to 800 mg EPA/day and 300 mg to 1 g DHA/day (9-11)
Brain and Visual Development*:
20-40 mg DHA/2.2 lb. body weight/day12
Preventive measures
- It is advisable not to take Omega-3
supplements if you are allergic to fish or gelatin
- It is advisable to tell your physician that you are
taking Omega-3 supplements if you are about to have
surgery or take anticoagulants
References
1. AHA: American Heart Association
2. ESC: European Society of Cardiology
3. Peet M, Horrobin DF. A dose-ranging
study of the effects of ethyl-eicosapentaenoate in patients
with ongoing depression despite apparently adequate
treatment with standard drugs. Arch Gen Psychiatry 2002;
59(10):913-9.
4. Osher Y, Bersudsky Y, Belmaker
RH. Omega-3 eicosapentaenoic acid in bipolar depression
: Report of a small open-label study. J Clin Psych 2005;
66(6):726-9.
5. Sagduyu K, Dokucu ME, Eddy BA,
Craigen G, Baldassano CF, Yildiz A. Omega-3 fatty acids
decreased irritability of patients with bipolar disorder
in an add-on, open label study. Nutr J 2005 Feb 9;4(1):6.
6. Peet M, Brind J, Ramchand CN,
Shah S, Vankar GK. Two double-blind placebo-controlled
pilot studies of eicosapentaenoic acid in the treatment
of schizophrenia. Schizophr Res. 2001 Apr 30;49(3):243-51.
7. Zanarini MC, Frankenburg FR. Omega-3
Fatty acid treatment of women with borderline personality
disorder: a double-blind, placebocontrolled pilot study.
Am J Psychiatry 2003; 160(1):167-9.
8. Richardson AJ. Clinical trials
of fatty acid treatment in ADHD, dyslexia, dyspraxia
and the autistic spectrum. Prostaglandins Leukot Essent
Fatty Acids 2004; 70(4):383-90.
9. Simopoulos AP. The importance
of the ratio of Omega-6/Omega-3 essential fatty acids.
Biomed Pharmacother 2002; 56(8):365-79.
10. Facchinetti F, Fazzio M, Venturini
P. Polyunsaturated fatty acids and risk of preterm delivery.
Eur Rev Med Pharmacol Sci 2005; 9(1):41-8.
11. Helland IB, Smith L, Saarem K,
Saugstad OD, Drevon CA. Maternal supplementation with
very-long-chain n-3 fatty acids during pregnancy and
lactation augments children’s IQ at 4 years of
age. Pediatrics 2003; 111(1):e39-44.
12. WHO: World Health Organisation.
Report of a joint expert FAO/WHO consultation, 1994.
|
